Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4

被引：0
|
作者：
Shin-ichi Kanamitsu
Kiyomi Ito
Carol E. Green
Charles A. Tyson
Noriaki Shimada
Yuichi Sugiyama
机构：
[1] University of Tokyo,Graduate School of Pharmaceutical Sciences
[2] Kitasato University,School of Pharmaceutical Sciences
[3] SRI International,Toxicology Laboratory
[4] Daiichi Pure Chemicals Co.,Research and Development Division
[5] LTD.,Graduate School of Pharmaceutical Sciences
[6] University of Tokyo,undefined
来源：
Pharmaceutical Research | 2000年 / 17卷
关键词：
drug interaction; mechanism-based inhibition; triazolam; erythromycin; physiologically-based pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. To quantitatively predict the in vivo interaction betweentriazolam and erythromycin, which involves mechanism-basedinhibition of CYP3A4, from in vitro studies using human liver microsomes(HLM) and recombinant human CYP3A4 (REC).
引用
收藏
页码：419 / 426
页数：7
相关论文
共 50 条
  • [31] The CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes
    Okubo, Maho
    Murayama, Norie
    Shimizu, Makiko
    Shimada, Tsutomu
    Guengerich, F. Peter
    Yamazaki, Hiroshi
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2013, 38 (03): : 349 - 354
  • [32] CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver
    Iwahori, T
    Matsuura, T
    Maehashi, H
    Sugo, K
    Saito, M
    Hosokawa, M
    Chiba, K
    Masaki, T
    Aizaki, H
    Ohkawa, M
    Suzuki, T
    HEPATOLOGY, 2003, 37 (03) : 665 - 673
  • [33] Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4
    Coller, JK
    Somogyi, AA
    Bochner, F
    XENOBIOTICA, 1999, 29 (10) : 973 - 986
  • [34] Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes
    H. Katsuki
    A. Hamada
    C. Nakamura
    K. Arimori
    M. Nakano
    European Journal of Clinical Pharmacology, 2001, 57 : 709 - 715
  • [35] Territrems B and C metabolism in human liver microsomes: Major role of CYP3A4 and CYP3A5
    Peng, FC
    Chang, CC
    Yang, CY
    Edwards, RJ
    Doehmer, J
    TOXICOLOGY, 2006, 218 (2-3) : 172 - 185
  • [36] Assessment of CYP3A4(3A4) contribution to bupropion (B) hydroxylation in human liver microsomes (HLMs).
    Faucette, S
    Hawke, R
    Shifflett, S
    LeCluyse, E
    Lindley, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 99 - 99
  • [37] Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes
    Katsuki, H
    Hamada, A
    Nakamura, C
    Arimori, K
    Nakano, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (10) : 709 - 715
  • [38] Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes
    Schirmer, Markus
    Rosenberger, Albert
    Klein, Kathrin
    Kulle, Bettina
    Toliat, Mohammad R.
    Nuernberg, Peter
    Zanger, Ulrich M.
    Wojnowski, Leszek
    PHARMACOGENOMICS, 2007, 8 (05) : 443 - 453
  • [39] In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin
    Riley, RJ
    Howbrook, D
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1997, 38 (04) : 189 - 193
  • [40] Methadone N-demethylation in human liver microsomes:: lack of stereoselectivity and involvement of CYP3A4
    Foster, DJR
    Somogyi, AA
    Bochner, F
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (04) : 403 - 412
12345